Business
Oobli granted FDA approval for Oubli Fruit Sweet Protein

Rafaela Sousa
26 March 2024
26 March 2024
Oobli granted FDA approval for Oubli Fruit Sweet Protein

Oobli, a developer of sweet proteins and sugar alternatives, has received a ‘No Questions’ letter from the US Food and Drug Administration (FDA) for its Oubli Fruit Sweet Protein.
The letter confirms Oobli’s self-affirmed Generally Recognized As Safe (GRAS) status for Oubli Fruit Sweet Protein, supporting its use as a sweetener for food and beverages.
Scientifically known as ‘brazzein,’ the protein is made via precision fermentation.
Jason Ryder, Oobli’s founder and CTO, said: “Oobli is changing the future of sweetness through the use of sweet proteins as a replacement for traditional cane sugar and other alternative sweeteners like aspartame, sucralose, stevia and erythritol”.
“The Oubli Fruit Sweet Protein is one of several sweet proteins that is derived from fruits primarily found in West Africa and other equatorial environments. Sweet proteins are a class of proteins that deliver a sugar-like sweetness but don’t affect blood sugar, insulin or the gut microbiome.”
Ali Wing, CEO of Oobli, added: “The ‘No Questions’ letter from the FDA is a further testament to the strong potential that sweet proteins have to disrupt our global dependence on sugar and alternative sweeteners”.
“The Oubli Fruit Sweet Protein can be safely used in various foods with support from the general scientific community and the FDA. It can replace 70% or more of sugar in most food and beverages such as sodas, teas, baked goods and more, making the opportunities to reduce our sugar consumption endless.”
#Oobli #US
Related news
PoLoPo partners with CSM Ingredients to bring egg protein to baking market
Molecular farming firm PoLoPo has has signed a Memorandum of Understanding with CSM Ingredients to bring its ovalbumin to the baking market.
Bon Vivant unveils ‘Europe’s first’ peer-reviewed LCA for precision-fermented milk proteins
Bon Vivant has conducted a peer-reviewed life cycle analysis (LCA) of its products with Lorie Hamelin, an independent expert from INRAE.
Navigating the future: Key insights from FPP Amsterdam 2024
Navigating the future: Key insights from FPP Amsterdam 2024
Business
Oobli granted FDA approval for Oubli Fruit Sweet Protein

Rafaela Sousa
26 March 2024